Fig. 6

HMGA2 knockdown results in the inhibition of human NF1 MPNST growth via MSI2 signalling inactivation in vivo. a Bioluminescence images illustrating a higher concentration of circulating cells in sites injected with control or shHMGA2 and MSI2 co-transfected cells (left thigh) than in sites injected with shHMGA2-transfected cells (right thigh) at 4 weeks. b and c The stable shHMGA2-transfected group displayed a significant reduction in tumour size. d Monitoring of tumour growth. Bioluminescence signals were quantified using Living Image software. The stable shHMGA2-transfected group displayed a significant reduction in tumour growth, while shHMGA2- and MSI2-cotransfected cells exhibited tumour growth reversal. e Xenograft tumours were removed, and HMGA2, MSI2, Ki67, Beclin1 and LC3 expression levels were assessed by IHC. Scale bar = 100 μm. The stable shHMGA2-transfected group showed less HMGA2, MSI2, Ki67, Beclin1 and LC3 staining, while shHMGA2 and MSI2 co-transfected cells reverse MSI2, Ki67, Beclin1 and LC3 staining. f Xenograft tumours were removed, and the protein expression levels of HMGA2, MSI2, Beclin1, BCL2 and LC3-II were assessed by WB. g Schematic representation of HMGA2-MSI2 signalling pathway-induced NF1 MPNST growth